Menu Search
Equities

Cipher Pharmaceuticals Inc

PHE:FRA

Cipher Pharmaceuticals Inc

Actions
  • Price (EUR)5.80
  • Today's Change-0.05 / -0.85%
  • Shares traded100.00
  • 1 Year change+161.26%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024 08:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

  • Revenue in CAD (TTM)29.07m
  • Net income in CAD28.00m
  • Incorporated2004
  • Employees6.00
  • Location
    Cipher Pharmaceuticals Inc5750 Explorer Drive,, Suite 404MISSISSAUGA L4W 0A9CanadaCAN
  • Phone+1 (905) 602-5840
  • Fax+1 (905) 602-5840
  • Websitehttps://www.cipherpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.